Zacks Investment Research
09 Oct 2026, 12:45 UTC · 1h ago
Impact · against what's priced in
Haemonetics' 17.5% jump reflects the market's reaction to the CSL rollout timeline, but the actual catalyst is largely absorbed into the current price. Modest projected EPS and revenue growth suggest limited further upside without a positive guidance revision in the upcoming earnings report.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish · 0 new · 3 priced in
CSL expects to complete the rollout of Haemonetics devices and disposables across all its U.S. plasma collection centers by the end of calendar 2027.
Priced inanalysis of recent price rally
More positive than 93% of claims this week
Haemonetics is expected to report quarterly earnings of $1.30 per share, a 2.4% increase year-over-year.
Priced in
Continue reading
5 related stories
The stock rallied 17.5% on CSL's plan to complete a device rollout by end-2027, though expected quarterly EPS growth of only 2.4% suggests the immediate financial impact is muted.
Read from the article alone
No priced-in read yet
CSL's commitment to a full US rollout of Haemonetics devices by 2027 provides a timeline for capital expenditure and operational transition, coinciding with a recent 15.2% decline in share price.
Read from the article alone
Scored by the NIS engine · methodology.
So whatThe modest 2.4% growth suggests limited EPS upside unless the next print includes a positive guidance revision.
More positive than 54% of claims this week
Haemonetics quarterly revenues are expected to be $346.84 million, representing a 6% increase from the year-ago quarter.
Priced inconsensus estimates for upcoming report
So whatTop-line growth of 6% outpaces the 2.4% EPS growth, indicating potential margin compression in the current quarter.
More positive than 48% of claims this week
Which stocks this story touches
More positive than 74% of relationship scores this week
[b_to_a] CSL is rolling out Haemonetics' devices and disposables across its U.S. plasma collection centers.
More positive than 74% of relationship scores this week
[a_to_b] Haemonetics has a supply agreement to provide devices and disposables to CSL's U.S. plasma collection centers.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
2h ago
−0.4%
Price flat so far
$0.6332 vs $0.6360 close before publication (Oct 8) · not market-adjusted
CRLBF chart →+0.3%
Price flat so far
$119.80 vs $119.47 close before publication (Oct 8) · not market-adjusted
HAE chart →
